Chimeric receptors broaden the therapeutic landscape for autoimmune disease

Affiliations

¹ Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA.
² Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, USA. mradic@uthsc.edu.

Comment

Terri H Finkel et al. Nat Rev Rheumatol. 2023 Jun.

. 2023 Jun;19(6):327-328.

doi: 10.1038/s41584-023-00968-8.

¹ Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA.
² Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, USA. mradic@uthsc.edu.

No abstract available

Comment on

CD19-targeted CAR T cells in refractory antisynthetase syndrome.
Müller F, Boeltz S, Knitza J, Aigner M, Völkl S, Kharboutli S, Reimann H, Taubmann J, Kretschmann S, Rösler W, Manger B, Wacker J, Mougiakakos D, Jabari S, Schröder R, Uder M, Roemer F, Krönke G, Mackensen A, Schett G. Müller F, et al. Lancet. 2023 Mar 11;401(10379):815-818. doi: 10.1016/S0140-6736(23)00023-5. Epub 2023 Feb 15. Lancet. 2023. PMID: 36930673 No abstract available.

1. Müller, F. et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet 401, 815–818 (2023). - DOI - PubMed
1. Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124–2132 (2022). - DOI - PubMed
1. Kansal, R. et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci. Transl. Med. 11, eaav1648 (2019). - DOI - PubMed - PMC
1. Schmelz, J. L. et al. Chimeric antigen receptor T-cell therapy’s role in antiphospholipid syndrome: a case report. Br. J. Haematol. 188, e5–e8 (2020). - DOI - PubMed
1. Zhang, W. et al. Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR. Stem Cell Rev. Rep. 17, 2120–2123 (2021). - DOI - PubMed - PMC